Table 3 Frequently reported AEs in the elderly population.

From: Frequently reported adverse events of rebamipide compared to other drugs for peptic ulcer and gastroesophageal reflux disease

AEs

Cases (rebamipide)

ROR (95% CI) vs. all A02Bs

ROR (95% CI) vs. H2RAs

ROR (95% CI)

vs. PPIs

Median time to events

Dyspepsia/indigestion/GI distress

391

2.24 (2.00, 2.52)

2.49 (2.17, 2.85)

2.11 (1.83, 2.43)

4 days

Somnolence

274

2.23 (1.94, 2.56)

1.76 (1.51, 2.05)

2.78 (2.30, 3.35)

3 days

Dry mouth

209

3.97 (3.30, 4.76)

10.26 (7.52, 14.01)

2.06 (1.69, 2.52)

4 days

Face edema

90

3.04 (2.32, 3.97)

4.25 (3.00, 6.02)

2.02 (1.49, 2.75)

3 days

Abnormal temperature sensation /hot flashes

55

2.44 (1.75, 3.39)

2.12 (1.47, 3.06)

2.36 (1.56, 3.57)

2 days

Generalized edema

52

2.85 (2.01, 4.04)

5.57 (3.36, 9.23)

1.55 (1.06, 2.27)

6 days

Flatulence

41

2.15 (1.48, 3.13)

3.06 (1.91, 4.89)

1.66 (1.07, 2.57)

4 days

Malaise/feeling queasy

36

2.22 (1.49, 3.32)

2.06 (1.31, 3.24)

2.37 (1.42, 3.97)

4 days

Purpura/petechia

22

2.14 (1.29, 3.58)

2.58 (1.40, 4.76)

1.44 (0.81, 2.57)

5 days

Thirst

18

4.71 (2.41, 9.23)

10.04 (3.40, 29.65)

2.58 (1.22, 5.46)

9 days

Periorbital edema

16

2.68 (1.43, 5.01)

2.54 (1.24, 5.21)

2.29 (1.07, 4.94)

3 days

  1. AE adverse event, CI confidence interval, GI gastrointestinal, H2RA histamine 2 receptor antagonist, PPI proton pump inhibitor, ROR reporting odds ratio.
  2. Not significant.